التفاصيل البيبلوغرافية
| العنوان: |
Novel anti‐evaporative lipid‐based formulation for dry eye disease treatment. |
| المؤلفون: |
Jäntti, Janika, Viitaja, Tuomo, Sevón, Julia, Lajunen, Tatu, Puranen, Jooseppi, Raitanen, Jan‐Erik, Viljanen, Mira, Paananen, Riku, Moilanen, Jukka, Ekholm, Filip, Ruponen, Marika |
| المصدر: |
Acta Ophthalmologica (1755375X); Jan2024 Supplement, Vol. 102, pN.PAG-N.PAG, 1p |
| مصطلحات موضوعية: |
DRY eye syndromes, THERAPEUTICS, OPTICAL coherence tomography, STAINS & staining (Microscopy), OPTICAL goods stores, BENZALKONIUM chloride |
| مستخلص: |
Purpose: The majority of dry eye disease (DED) patients suffer from the tear film lipid layer (TFLL) instability issues associated with increased evaporation of water from the ocular surface. Therefore, we developed a liposomal formulation based on selected TFLL lipid classes that would restore the tear film stability and retard the evaporation of the aqueous tear fluid. Methods: The liposomal formulation was prepared by the thin film hydration method and subsequently characterized intermittently by standard techniques for at least 6 months. The mitochondrial metabolic activity (MTT) assay with human corneal epithelial (HCE) cells was utilized to assess the formulation toxicity in vitro. The evaporation resistance properties of the formulation were determined in vitro by the Langmuir trough methods, while a DED cellular model engendered by exposing the HCE cells to benzalkonium chloride (BAC) enabled additional assessment of the in vitro efficacy. In vivo safety was evaluated in rats and rabbits in one‐week studies. The conditions of the animal eyes were assessed by a non‐invasive biomicroscope, an optical coherence tomography, and histological staining of the dissected eyes. Results: The lipid‐based formulation with favourable pharmaceutical and functional properties (e.g., the evaporation resistance, and the promotion of HCE cell recovery after damage) was developed successfully, while also the physical stability of the formulation was found promising. No evidence of toxicity was observed during in vitro and in vivo experiments. Conclusions: The results suggest that the developed formulation is well‐tolerated and possesses properties and a safety profile compatible with ocular administration. Utilized in vitro efficacy models imply that the developed formulation is a promising candidate towards more efficient DED treatment. In vivo efficacy remains to be clarified in future studies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Ophthalmologica (1755375X) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder